Biotech entity
Every one of those 3 sits in a single category, fda-approval. Of the tracked stories, 2 of 3 also mention FDA, the most common co-covered peer. Each carries 2.3 original sources on average. We currently track 3 Biotech stories that mention Stéphane Bancel, all published on August 6, 2026.
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, fda-approval. Of the tracked stories, 2 of 3 also mention FDA, the most common co-covered peer. Each carries 2.3 original sources on average. We currently track 3 Biotech stories that mention Stéphane Bancel, all published on August 6, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Stéphane Bancel. Shared-story counts are live from our verified record — not editorial picks.
FDA Approval of mRNA-1010
The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.
Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Source: livescience.com · MedPage Today
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
The U.S. FDA approved Moderna's mFLUSIVA, an mRNA seasonal influenza vaccine, for adults 50 and older. Data from two randomized trials, including a 40,805-subject Phase 3, supported the approval, with the 65+ cohort receiving accelerated approval. This milestone validates the mRNA platform beyond COVID-19 and positions Moderna to compete in the $5 billion+ global flu vaccine market.
Source: finanznachrichten.de · pr-inside.com
Stéphane Bancel is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
